iTeos Therapeutics Inc. (ITOS)
7.88
0.22 (2.87%)
At close: Jan 15, 2025, 9:49 AM
Company Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.
The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
iTeos Therapeutics Inc.
| Country | United States |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 157 |
| CEO | Dr. Michel Detheux Ph.D. |
Contact Details
Address: 321 Arsenal Street Cambridge, Massachusetts United States | |
| Website | https://www.iteostherapeutics.com |
Stock Details
| Ticker Symbol | ITOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001808865 |
| CUSIP Number | 46565G104 |
| ISIN Number | US46565G1040 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michel Detheux Ph.D. | President, Chief Executive Officer & Director |
| Matthew Gall | Chief Financial Officer |
| Matthew A. Call M.B.A. | Chief Operating Officer |
| Adi Osovsky | Executive Vice President of Legal |
| Dr. David Feltquate M.D., Ph.D. | Chief Medical Officer |
| Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer |
| Philippe Brantegem | Executive Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Dec 06, 2024 | 4 | Filing |
| Nov 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 19, 2024 | 4 | Filing |
| Nov 18, 2024 | SC 13D/A | [Amend] Filing |
| Nov 18, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 04, 2024 | 8-K | Current Report |